Enliven Therapeutics Inc. (ELVN) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Enliven Therapeutics Inc. (NASDAQ: ELVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $44.63 (+0.86% 1D, market cap $3.24B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ELVN ranks #481 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELVN carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -26.2%. By comparison, DYN (Dyne Therapeutics Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.12B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per ELVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672619), Enliven Therapeutics Inc. generated $335.0M in revenue (+14.4% YoY), -$103.7M in net income, and -$70.3M in free cash flow against $476.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 63% of 52W Range • RSI-14 at 50.7 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ELVN currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($48.07) and Max Pain ($46.86) forces dealer call-delta covering toward $65.44.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Enliven Therapeutics Inc. (ELVN) advanced +0.86% to $44.63, trading at 63% of its 52-week range ($14.78 – $62.32). Stretched risk/reward at current multiples (-26% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of K
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +14.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELVN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELVN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Enliven Therapeutics Inc. (ELVN) ranks #481 by composite RQD confidence (39/100, grade D-) and #197 by equity capitalization ($3.24B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with ELVN at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELVN
ACTIVE
Enliven Therapeutics Inc. | D- | 39/100 | — | — | -26.2% | +0.86% | $3.24B | Benchmark Subject |
| DYN Dyne Therapeutics Inc. | E | 26/100 | — | — | -35.0% | +3.66% | $3.12B | /dyn-vs-elvn → |
| IDYA IDEAYA Biosciences Inc. | E | 34/100 | — | — | -13.8% | -1.00% | $3.08B | /idya-vs-elvn → |
| TLX Telix Pharmaceuticals Limited | D | 47/100 | — | — | — | -0.55% | $3.08B | /tlx-vs-elvn → |
| BHC Bausch Health Companies Inc. | C+ | 68/100 | 21.2x | — | 7.6% | -2.19% | $3.07B | /bhc-vs-elvn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enliven Therapeutics Inc. (ELVN) reported GAAP revenue of $335.0M (+14.4% vs. FY2024 revenue of $292.8M , and +43.3% cumulative change since FY2023) , GAAP net income of -$103.7M, operating cash flow of -$70.3M, and free cash flow of -$70.3M (+3.9% YoY). On the balance sheet, ELVN closed FY2025 with $476.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $335.0M | -$103.7M | -$70.3M | -$70.3M | $476.2M | — |
| FY2024 (FY) | 2024-12-31 | $292.8M | -$89.0M | -$73.2M | -$73.2M | $325.8M | — |
| FY2023 (FY) | 2023-12-31 | $233.9M | -$71.6M | -$61.3M | -$61.3M | — | — |
As of 2026-11-03, Enliven Therapeutics Inc. (NASDAQ: ELVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $44.63 (+0.86% 1D, market cap $3.24B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ELVN ranks #481 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELVN carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -26.2%. By comparison, DYN (Dyne Therapeutics Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.12B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per ELVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672619), Enliven Therapeutics Inc. generated $335.0M in revenue (+14.4% YoY), -$103.7M in net income, and -$70.3M in free cash flow against $476.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ELVN last traded at $44.63 (+0.86% on volume of 1,138,673 shares), positioning the stock -7.16% below its 50-day simple moving average ($48.07) and +3.98% above its 200-day simple moving average ($42.92). Across its 52-week range of $14.78 to $62.32, ELVN sits at the 62.8% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.4% ($40.88 to $48.38).
Enliven Therapeutics Inc. (ELVN) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $44.63 (+0.86% 1D, market capitalization $3.24B).
Enliven Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company carries a market capitalization of $3.3B. Per the news section, its lead program referenced is relacobatinib (ELVN-001) for previously treated chronic myeloid leukemia, with a Phase 3 trial design (ENABLE-2) reported as aligned with the FDA. The FY 2025 and FY 2024 financials report — revenue, indicating no reported revenue in those periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Enliven Therapeutics Inc. (ELVN) reported $335.0M in annual revenue (up from $292.8M in FY2024, +14.4% YoY) and -$103.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($233.9M revenue, -$71.6M net income) through FY2025, ELVN scaled operating cash flow to -$70.3M and free cash flow to -$70.3M, backed by $476.2M in total assets against $0 in total debt.
Upstream and downstream dependencies cannot be mapped from the source data. — for sector correlation coefficients.
Real-time company headlines, analyst actions, and sector developments for Enliven Therapeutics Inc. (ELVN) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Enliven Therapeutics Inc. (ELVN) market action, institutional positioning, and fundamental catalysts.
FDA alignment on the ENABLE-2 Phase 3 design for relacobatinib in previously treated CML is the sharpest near-term catalyst in the feed.. When you look under the hood at ELVN, Fundamental Cash Engine is 7/20 with 0.0% gross margins and -26.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (9/20) has been quietly accumulating below $62.32. My 12M target is $56.20.
@FadeTheHype Shorting a 9/20 institutional whale-flow stock at $44.25 is dangerous when funds are rotating into Health Care.
Here is the bear case nobody on the bull side wants to address on ELVN: A -26.2% ROIC, -2.13% FCF yield, and a 3 / 20 insider conviction score point to a cash engine that is burning capital with weak insider backing.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: